Indicator type	Size of the company	Total
Number of companies carrying out R&D in Biotechnology	Less than 250 employees	1.284
Number of companies carrying out R&D in Biotechnology	250 and more employees	160
Number of companies carrying out R&D in Biotechnology	Total	1.444
% Companies by type of biotechnology used: Genetic Code	Less than 250 employees	29,7
% Companies by type of biotechnology used: Genetic Code	250 and more employees	38,6
% Companies by type of biotechnology used: Genetic Code	Total	30,7
% Companies by type of biotechnology used: Functional Units	Less than 250 employees	36,6
% Companies by type of biotechnology used: Functional Units	250 and more employees	45,5
% Companies by type of biotechnology used: Functional Units	Total	37,6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Less than 250 employees	20
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	250 and more employees	31,6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Total	21,3
% Companies by type of biotechnology used: Bioprocesses	Less than 250 employees	49,5
% Companies by type of biotechnology used: Bioprocesses	250 and more employees	62,6
% Companies by type of biotechnology used: Bioprocesses	Total	50,9
% Companies by type of biotechnology used: Subcellular Organisms	Less than 250 employees	6,8
% Companies by type of biotechnology used: Subcellular Organisms	250 and more employees	18,3
% Companies by type of biotechnology used: Subcellular Organisms	Total	8,1
% Companies by type of biotechnology used: Bioinformatics	Less than 250 employees	22,1
% Companies by type of biotechnology used: Bioinformatics	250 and more employees	26,6
% Companies by type of biotechnology used: Bioinformatics	Total	22,6
% Companies by type of biotechnology used: Nanobiotechnology	Less than 250 employees	9,8
% Companies by type of biotechnology used: Nanobiotechnology	250 and more employees	10,2
% Companies by type of biotechnology used: Nanobiotechnology	Total	9,8
% Companies by type of biotechnology used: Other	Less than 250 employees	16,8
% Companies by type of biotechnology used: Other	250 and more employees	17,2
% Companies by type of biotechnology used: Other	Total	16,9
Companies in which biotechnology activities are: Main and/or exclusive	Less than 250 employees	604
Companies in which biotechnology activities are: Main and/or exclusive	250 and more employees	25
Companies in which biotechnology activities are: Main and/or exclusive	Total	629
Companies in which biotechnology activities are: A secondary business line	Less than 250 employees	215
Companies in which biotechnology activities are: A secondary business line	250 and more employees	47
Companies in which biotechnology activities are: A secondary business line	Total	262
Companies in which biotechnology activities are: A necessary tool for production	Less than 250 employees	465
Companies in which biotechnology activities are: A necessary tool for production	250 and more employees	88
Companies in which biotechnology activities are: A necessary tool for production	Total	553
% Companies by final application areas of biotechnology use: Human Health	Less than 250 employees	44,7
% Companies by final application areas of biotechnology use: Human Health	250 and more employees	41,1
% Companies by final application areas of biotechnology use: Human Health	Total	44,3
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Less than 250 employees	16,2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	250 and more employees	12,1
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Total	15,8
% Companies by final application areas of biotechnology use: Food Products	Less than 250 employees	29,4
% Companies by final application areas of biotechnology use: Food Products	250 and more employees	41,1
% Companies by final application areas of biotechnology use: Food Products	Total	30,7
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Less than 250 employees	25,6
% Companies by final application areas of biotechnology use: Agriculture and Forestry	250 and more employees	20,1
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Total	24,9
% Companies by final application areas of biotechnology use: Environment	Less than 250 employees	17,3
% Companies by final application areas of biotechnology use: Environment	250 and more employees	13,9
% Companies by final application areas of biotechnology use: Environment	Total	16,9
% Companies by final application areas of biotechnology use: Industry	Less than 250 employees	12,5
% Companies by final application areas of biotechnology use: Industry	250 and more employees	13,3
% Companies by final application areas of biotechnology use: Industry	Total	12,6
R&D personnel in Biotechnology (PP)	Less than 250 employees	10.452
R&D personnel in Biotechnology (PP)	250 and more employees	7.291
R&D personnel in Biotechnology (PP)	Total	17.743
R&D personnel in Biotechnology (PP): Research personnel	Less than 250 employees	6.309
R&D personnel in Biotechnology (PP): Research personnel	250 and more employees	3.136
R&D personnel in Biotechnology (PP): Research personnel	Total	9.445
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Less than 250 employees	4.144
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	250 and more employees	4.154
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Total	8.298
R&D personnel in Biotechnology (PP). Women	Less than 250 employees	5.369
R&D personnel in Biotechnology (PP). Women	250 and more employees	4.538
R&D personnel in Biotechnology (PP). Women	Total	9.907
R&D personnel in Biotechnology (PP). Women: Research personnel	Less than 250 employees	3.273
R&D personnel in Biotechnology (PP). Women: Research personnel	250 and more employees	1.832
R&D personnel in Biotechnology (PP). Women: Research personnel	Total	5.104
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Less than 250 employees	2.096
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	250 and more employees	2.707
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Total	4.802
R&D personnel in Biotechnology (FTE)	Less than 250 employees	7.232,7
R&D personnel in Biotechnology (FTE)	250 and more employees	5.760,8
R&D personnel in Biotechnology (FTE)	Total	12.993,4
R&D personnel in Biotechnology (FTE): Research personnel	Less than 250 employees	4.671,5
R&D personnel in Biotechnology (FTE): Research personnel	250 and more employees	2.398,3
R&D personnel in Biotechnology (FTE): Research personnel	Total	7.069,9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Less than 250 employees	2.561,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	250 and more employees	3.362,4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Total	5.923,6
R&D personnel in Biotechnology (FTE). Women	Less than 250 employees	3.763,9
R&D personnel in Biotechnology (FTE). Women	250 and more employees	3.707,8
R&D personnel in Biotechnology (FTE). Women	Total	7.471,8
R&D personnel in Biotechnology (FTE). Women: Research personnel	Less than 250 employees	2.449,2
R&D personnel in Biotechnology (FTE). Women: Research personnel	250 and more employees	1.421
R&D personnel in Biotechnology (FTE). Women: Research personnel	Total	3.870,1
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Less than 250 employees	1.314,8
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	250 and more employees	2.286,9
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Total	3.601,6
Expenditure on internal R&D in Biotechnology (thousands of euros)	Less than 250 employees	691.268
Expenditure on internal R&D in Biotechnology (thousands of euros)	250 and more employees	532.533
Expenditure on internal R&D in Biotechnology (thousands of euros)	Total	1.223.801
1) By type of expenditure: Current expenditure	Less than 250 employees	614.656
1) By type of expenditure: Current expenditure	250 and more employees	493.534
1) By type of expenditure: Current expenditure	Total	1.108.189
1.1) Labour expenditure of research personnel	Less than 250 employees	221.957
1.1) Labour expenditure of research personnel	250 and more employees	138.965
1.1) Labour expenditure of research personnel	Total	360.922
1.2) Labour expenditure of technical and auxiliary personnel	Less than 250 employees	96.161
1.2) Labour expenditure of technical and auxiliary personnel	250 and more employees	124.379
1.2) Labour expenditure of technical and auxiliary personnel	Total	220.540
1.3) Other current expenditure	Less than 250 employees	296.538
1.3) Other current expenditure	250 and more employees	230.190
1.3) Other current expenditure	Total	526.727
2) By type of expenditure: Capital expenditure	Less than 250 employees	76.612
2) By type of expenditure: Capital expenditure	250 and more employees	39.000
2) By type of expenditure: Capital expenditure	Total	115.612
2.1) Land and buildings	Less than 250 employees	7.247
2.1) Land and buildings	250 and more employees	9.596
2.1) Land and buildings	Total	16.843
2.2) Equipment and tools	Less than 250 employees	37.708
2.2) Equipment and tools	250 and more employees	25.819
2.2) Equipment and tools	Total	63.527
2.3) Acquisition of specific R&D software	Less than 250 employees	2.767
2.3) Acquisition of specific R&D software	250 and more employees	1.191
2.3) Acquisition of specific R&D software	Total	3.959
2.4) Other R&D-specific IP products	Less than 250 employees	28.890
2.4) Other R&D-specific IP products	250 and more employees	2.394
2.4) Other R&D-specific IP products	Total	31.284
1.1) By origin of funds: Own funds	Less than 250 employees	471.465
1.1) By origin of funds: Own funds	250 and more employees	389.138
1.1) By origin of funds: Own funds	Total	860.603
1.2) By origin of funds: Funds from the Business sector	Less than 250 employees	77.630
1.2) By origin of funds: Funds from the Business sector	250 and more employees	50.371
1.2) By origin of funds: Funds from the Business sector	Total	128.002
1.3) By origin of funds: Funds from the Public Administration sector	Less than 250 employees	96.976
1.3) By origin of funds: Funds from the Public Administration sector	250 and more employees	22.523
1.3) By origin of funds: Funds from the Public Administration sector	Total	119.498
1.4) By origin of funds: Funds from the Higher Education sector	Less than 250 employees	647
1.4) By origin of funds: Funds from the Higher Education sector	250 and more employees	0
1.4) By origin of funds: Funds from the Higher Education sector	Total	647
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Less than 250 employees	1.563
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	250 and more employees	11.423
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Total	12.986
1.6) By origin of funds: Funds from the rest of the world	Less than 250 employees	42.988
1.6) By origin of funds: Funds from the rest of the world	250 and more employees	59.078
1.6) By origin of funds: Funds from the rest of the world	Total	102.065
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Less than 250 employees	43.120
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	250 and more employees	80.276
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Total	123.396
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Less than 250 employees	22.993
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	250 and more employees	65.992
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Total	88.985
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Less than 250 employees	20.127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	250 and more employees	14.284
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Total	34.412
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Less than 250 employees	41,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	250 and more employees	23,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Total	39,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Less than 250 employees	15,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	250 and more employees	16,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Total	15,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Less than 250 employees	22,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	250 and more employees	17,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Total	22,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Less than 250 employees	11,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	250 and more employees	17
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Total	12,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Less than 250 employees	17,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	250 and more employees	15,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Total	17,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Less than 250 employees	18,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	250 and more employees	15,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Total	17,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Less than 250 employees	15,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	250 and more employees	20,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Total	16
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Less than 250 employees	41,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	250 and more employees	38,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Total	41,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Less than 250 employees	51
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	250 and more employees	44,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Total	50,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Less than 250 employees	20,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	250 and more employees	15,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Total	20,1
% Companies with international revenues related to biotechnology activities	Less than 250 employees	23
% Companies with international revenues related to biotechnology activities	250 and more employees	20,2
% Companies with international revenues related to biotechnology activities	Total	22,7
% Companies representing international revenues related to biotechnology activities	Less than 250 employees	8,2
% Companies representing international revenues related to biotechnology activities	250 and more employees	1,3
% Companies representing international revenues related to biotechnology activities	Total	2,1
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Less than 250 employees	55,4
% International revenues related to biotechnology activities distributed in: Revenues from the EU	250 and more employees	64,9
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Total	60,6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Less than 250 employees	44,6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	250 and more employees	35,1
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Total	39,4
% International revenues related to biotechnology activities by classification: International trade in goods and services	Less than 250 employees	93,9
% International revenues related to biotechnology activities by classification: International trade in goods and services	250 and more employees	82,8
% International revenues related to biotechnology activities by classification: International trade in goods and services	Total	87,8
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Less than 250 employees	3,8
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	250 and more employees	15,1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total	10,1
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Less than 250 employees	0,7
% International revenues related to biotechnology activities by classification: Subsidies from external sources	250 and more employees	2
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Total	1,4
% International revenues related to biotechnology activities by classification: Other	Less than 250 employees	1,7
% International revenues related to biotechnology activities by classification: Other	250 and more employees	0
% International revenues related to biotechnology activities by classification: Other	Total	0,8